粒细胞型髓系抑制细胞与固有淋巴细胞在系统性硬化症中的协同作用
该研究分析系统性硬化症(SSc)患者外周血和皮肤活检样本,结合小鼠纤维化模型及单细胞转录组数据,发现粒细胞型髓系抑制细胞(G-MDSC)在SSc循环和皮肤中富集并与疾病严重程度相关,且通过IL-13驱动的TGFβ、精氨酸酶1和CCL24与2型固有淋巴细胞(ILC2)相互作用促进纤维化。
要点
- G-MDSC在SSc患者循环和皮肤中显著富集,且与疾病严重程度相关。
- G-MDSC通过IL-13驱动的TGFβ、精氨酸酶1和CCL24与ILC2相互作用,促进促纤维化环境。
- 靶向G-MDSC-ILC2轴可能成为缓解SSc纤维化进展的新治疗策略。
核心结论
- G-MDSC-ILC2轴是SSc纤维化的驱动因素,靶向该相互作用可能成为缓解纤维化疾病进展的新治疗策略。
研究设计与样本
- 研究纳入SSc患者外周血(SSc N=37,健康 N=27)和皮肤活检(SSc N=9,健康 N=5),采用流式细胞术和荧光显微镜分析。
- 使用博来霉素诱导的小鼠纤维化模型验证发现,包括通过布鲁顿酪氨酸激酶抑制(依鲁替尼)药理学干扰G-MDSC活性。
- 整合SSc和对照皮肤及肺样本的单细胞RNA测序数据(皮肤:19例SSc,20例健康;肺:7例SSc,15例健康),辅以皮肤空间转录组分析(12例SSc,7例健康)。
- 进行功能研究和批量RNA测序以剖析G-MDSC相互作用。
主要发现
- G-MDSC在SSc患者循环和皮肤中显著富集,并与疾病严重程度相关。
- 实验性纤维化显示G-MDSC富集,而单核细胞型MDSC保持稳定。
- 转录组数据揭示MDSC与2型固有淋巴细胞(ILC2)之间强相互作用,通过IL-13驱动的TGFβ、精氨酸酶1和CCL24促进促纤维化环境。
- 功能实验证实G-MDSC促进ILC2中Tgfb1表达,进一步驱动组织纤维化。
关键数值与推荐
- SSc患者外周血样本量:SSc N=37,健康 N=27。
- SSc患者皮肤活检样本量:SSc N=9,健康 N=5。
- 单细胞RNA测序样本量:皮肤19例SSc和20例健康,肺7例SSc和15例健康。
- 空间转录组分析皮肤样本量:12例SSc和7例健康。
临床怎么用
- G-MDSC在SSc循环和皮肤中富集且与疾病严重程度相关,可作为疾病活动度的潜在生物标志物。
- 靶向G-MDSC-ILC2相互作用(如通过布鲁顿酪氨酸激酶抑制)可能成为缓解SSc纤维化进展的治疗策略。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid-derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc-associated fibrosis and their interactions with other immune cell populations remain poorly understood. METHODS: Peripheral blood (SSc: N=37, healthy: N=27) and skin biopsies (SSc: N=9, healthy: N=5) were analyzed using flow cytometry and fluorescence microscopy, respectively. Bleomycin-induced mouse models of fibrosis were used to validate findings, including pharmacological disruption of granulocytic MDSC (G-MDSC) activity via Bruton's tyrosine kinase inhibition (ibrutinib). Single-cell RNA sequencing data from SSc and control skin and lung samples (skin: 19 SSc, 20 healthy; lung: 7 SSc, 15 healthy), complemented by spatial transcriptomics analysis of skin (12 SSc, 7 healthy), were integrated to define cellular interactions relevant to disease pathogenesis. Functional studies and bulk RNA sequencing were conducted to dissect the underlying G-MDSC interactions. RESULTS: G-MDSCs were significantly enriched in the circulation and skin of SSc patients, correlating with disease severity. Experimental fibrosis revealed enrichment of G-MDSCs, whereas monocytic MDSCs remained stable. Transcriptomic data revealed a strong interaction between MDSCs and type 2 innate lymphoid cells (ILC2s), promoting a pro-fibrotic environment via IL-13-driven TGFβ, Arginase1 and CCL24. Functional assays confirmed that G-MDSCs promote Tgfb1 expression in ILC2s, further driving tissue fibrosis. CONCLUSION: These findings explore a so far unknown G-MDSC-ILC2 axis as a driver of fibrosis in SSc. Targeting this interaction may represent a novel therapeutic strategy to mitigate fibrotic disease progression.
引用
- Weber S, Angeli MR, Mohammadian H, et al. The synergistic impact of granulocytic myeloid-derived suppressor cells and innate lymphoid cells in systemic sclerosis. Arthritis Rheumatol. 2026. PMID: 42703771. doi:10.1002/art.70325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。